These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

306 related items for PubMed ID: 17296470

  • 1. Cost effectiveness of pertussis vaccination in adults.
    Lee GM, Murphy TV, Lett S, Cortese MM, Kretsinger K, Schauer S, Lieu TA.
    Am J Prev Med; 2007 Mar; 32(3):186-193. PubMed ID: 17296470
    [Abstract] [Full Text] [Related]

  • 2. Pertussis in adolescents and adults: should we vaccinate?
    Lee GM, Lebaron C, Murphy TV, Lett S, Schauer S, Lieu TA.
    Pediatrics; 2005 Jun; 115(6):1675-84. PubMed ID: 15930232
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis.
    Purdy KW, Hay JW, Botteman MF, Ward JI.
    Clin Infect Dis; 2004 Jul 01; 39(1):20-8. PubMed ID: 15206048
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of adult pertussis vaccination in Germany.
    Lee GM, Riffelmann M, Wirsing von Konig CH.
    Vaccine; 2008 Jul 04; 26(29-30):3673-9. PubMed ID: 18538901
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
    Ortega-Sanchez IR, Meltzer MI, Shepard C, Zell E, Messonnier ML, Bilukha O, Zhang X, Stephens DS, Messonnier NE, Active Bacterial Core Surveillance Team.
    Clin Infect Dis; 2008 Jan 01; 46(1):1-13. PubMed ID: 18171206
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
    Shepard CW, Ortega-Sanchez IR, Scott RD, Rosenstein NE, ABCs Team.
    Pediatrics; 2005 May 01; 115(5):1220-32. PubMed ID: 15867028
    [Abstract] [Full Text] [Related]

  • 13. Economic evaluation of an extended acellular pertussis vaccine programme for adolescents in Ontario, Canada.
    Iskedjian M, Walker JH, Hemels ME.
    Vaccine; 2004 Oct 22; 22(31-32):4215-27. PubMed ID: 15474711
    [Abstract] [Full Text] [Related]

  • 14. Economic analysis of pertussis illness in the Dutch population: implications for current and future vaccination strategies.
    de Greeff SC, Lugnér AK, van den Heuvel DM, Mooi FR, de Melker HE.
    Vaccine; 2009 Mar 18; 27(13):1932-7. PubMed ID: 19368774
    [Abstract] [Full Text] [Related]

  • 15. Economic impact of the introduction of an acellular pertussis vaccine in Canada: a 6-year analysis.
    Iskedjian M, De Serres G, Einarson TR, Walker JH.
    Vaccine; 2010 Jan 08; 28(3):714-23. PubMed ID: 19895923
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Mass vaccination of children with pertussis toxoid--decreased incidence in both vaccinated and nonvaccinated persons.
    Taranger J, Trollfors B, Bergfors E, Knutsson N, Sundh V, Lagergård T, Lind-Brandberg L, Zackrisson G, White J, Cicirello H, Fusco J, Robbins JB.
    Clin Infect Dis; 2001 Oct 01; 33(7):1004-10. PubMed ID: 11528572
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [[Health and economic benefits of mandatory regular vaccination in the Slovak Republic. III. Diphtheria, tetanus and pertussis] ].
    Hudecková H, Straka S, Szilágyiová M, Rusnáková S.
    Epidemiol Mikrobiol Imunol; 2000 Nov 01; 49(4):153-7. PubMed ID: 11188762
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.